Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Segments - Segment Information (Details)

v3.19.3
Note 15 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Revenue from contract with customer $ 5,000     $ 22,000     $ 35,000 $ 303,000  
Grant and other revenue 231,916     209,146     514,589 762,549  
Revenue 236,811     231,458     538,527 1,050,030  
Cost of revenue 195     38,101     6,559 73,811  
Research and development expenses 1,801,558     1,225,770     3,612,783 3,367,444  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,485,207     2,651,113     5,001,818 6,141,386  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 34,289     37,590     107,794 113,088  
(Loss) income from operations (3) [3] (3,084,438)     (3,721,116)     (8,190,427) (8,645,699)  
Other income (4) [4] 10,334     (24,534)     17,456 (4,284,014)  
Provision for income taxes     (76,259)     (707) (65,330)  
Net (loss) income (3,074,104) $ (2,673,179) $ (2,429,061) (3,821,909) $ (2,394,057) $ (6,737,962) (8,176,343) (12,953,928)  
Total assets, net of depreciation and amortization 4,821,656           4,821,656   $ 7,021,527
Capital expenditures     16,152     19,317  
Net income (loss) (3,074,104) $ (2,673,179) $ (2,429,061) (3,821,909) $ (2,394,057) $ (6,737,962) (8,176,343) (12,953,928)  
Net loss from continuing operations             (8,173,678) (12,995,043)  
Loss from discontinued operations, net of tax             (2,665) (1,938)  
Gain on sale of discontinued operations, net of tax         43,053  
UNITED STATES                  
Total assets, net of depreciation and amortization 4,819,050     9,089,645     4,819,050 9,089,645  
Non-US [Member]                  
Total assets, net of depreciation and amortization 2,606     19,397     2,606 19,397  
Royalty [Member]                  
Revenue from contract with customer 4,895     2,382     13,985 9,842  
License [Member]                  
Revenue from contract with customer     19,930     9,953 277,639  
Diagnostics Segment [Member]                  
Grant and other revenue 77,049     65,505     309,670 454,830  
Revenue 81,944     87,817     333,608 742,311  
Cost of revenue 195     38,101     6,559 73,811  
Research and development expenses 1,678,423     711,355     3,194,468 2,409,524  
Selling, general and administrative expenses, excluding depreciation and amortization [1]          
Depreciation, Depletion and Amortization, Nonproduction, Total [2]          
(Loss) income from operations (3) [3] (1,596,674)     (661,639)     (2,867,419) (1,741,024)  
Other income (4) [4]          
Provision for income taxes (72)     (10,081)     (248) (8,797)  
Net (loss) income (1,596,746)     (671,720)     (2,870,332) (1,708,706)  
Capital expenditures          
Net income (loss) (1,596,746)     (671,720)     (2,870,332) (1,708,706)  
Net loss from continuing operations             (2,867,667) (1,749,821)  
Loss from discontinued operations, net of tax             (2,665) (1,938)  
Gain on sale of discontinued operations, net of tax               43,053  
Diagnostics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 36,811     117,722     36,811 117,722  
Diagnostics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization 2,606     18,239     2,606 18,239  
Diagnostics Segment [Member] | Royalty [Member]                  
Revenue from contract with customer 4,895     2,382     13,985 9,842  
Diagnostics Segment [Member] | License [Member]                  
Revenue from contract with customer       19,930     9,953 277,639  
Therapeutics Segment [Member]                  
Grant and other revenue 154,867     143,641     204,919 307,719  
Revenue 154,867     143,641     204,919 307,719  
Cost of revenue          
Research and development expenses 123,135     514,415     418,315 957,920  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,052     20,532     15,828 45,769  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]          
(Loss) income from operations (3) [3] 30,680     (391,306)     (229,224) (695,970)  
Other income (4) [4]          
Provision for income taxes 16     (3,879)     (20) (3,517)  
Net (loss) income 30,696     (395,185)     (229,244) (699,487)  
Capital expenditures          
Net income (loss) 30,696     (395,185)     (229,244) (699,487)  
Net loss from continuing operations             (229,244) (699,487)  
Loss from discontinued operations, net of tax              
Gain on sale of discontinued operations, net of tax                
Therapeutics Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 93,860     72,622     93,860 72,622  
Therapeutics Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization          
Therapeutics Segment [Member] | Royalty [Member]                  
Revenue from contract with customer          
Therapeutics Segment [Member] | License [Member]                  
Revenue from contract with customer            
Corporate Segment [Member]                  
Grant and other revenue          
Revenue          
Cost of revenue          
Research and development expenses          
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,484,155     2,630,581     4,985,990 6,095,617  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 34,289     37,590     107,794 113,088  
(Loss) income from operations (3) [3] (1,518,444)     (2,668,171)     (5,093,784) (6,208,705)  
Other income (4) [4] 10,334     (24,534)     17,456 (4,284,014)  
Provision for income taxes 55     (62,299)     (439) (53,017)  
Net (loss) income (1,508,055)     (2,755,004)     (5,076,767) (10,545,736)  
Capital expenditures     16,152     19,317  
Net income (loss) (1,508,055)     (2,755,004)     (5,076,767) (10,545,736)  
Net loss from continuing operations             (5,076,767) (10,545,736)  
Loss from discontinued operations, net of tax              
Gain on sale of discontinued operations, net of tax                
Corporate Segment [Member] | UNITED STATES                  
Total assets, net of depreciation and amortization 4,688,379     8,899,301     4,688,379 8,899,301  
Corporate Segment [Member] | Non-US [Member]                  
Total assets, net of depreciation and amortization     1,158     1,158  
Corporate Segment [Member] | Royalty [Member]                  
Revenue from contract with customer          
Corporate Segment [Member] | License [Member]                  
Revenue from contract with customer            
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($34,289 and $37,590 for the three-month periods ended September 30, 2019 and 2018, and $107,794 and $113,088 for the nine-month periods ended September 30, 2019 and 2018, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.